Research for evaluation of efficacy and safety of DAA therapy in HIV/HCV co-infected patients disorders
Latest Information Update: 23 May 2019
Price :
$35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 26 May 2017 New trial record